Presentation is loading. Please wait.

Presentation is loading. Please wait.

PSYC 342: Psychopharmacology ANTIPSYCHOTIC MEDICATIONS.

Similar presentations


Presentation on theme: "PSYC 342: Psychopharmacology ANTIPSYCHOTIC MEDICATIONS."— Presentation transcript:

1 PSYC 342: Psychopharmacology ANTIPSYCHOTIC MEDICATIONS

2 Primary Indication for Use: Schizophrenia Positive symptoms * Delusions Hallucinations Cognitive deficits * Attention Memory Verbal fluency Executive function (eg, abstraction) Functional Impairments Work/school Interpersonal relationships Self-care Negative symptoms * Anhedonia Affective flattening Avolition Social withdrawal Alogia Mood symptoms Depression/Anxiety Aggression/Hostility Suicidality Disorganization Speech Behavior

3 DSM IV-TR Diagnostic Criteria 2 or more of the following for most of 1 month: –Delusions –Hallucinations –Disorganized speech –Grossly disorganized or catatonic behavior –Negative symptoms Social/occupational dysfunction Duration of at least 6 months Not schizoaffective disorder or a mood disorder with psychotic features Not due to substance abuse or a general medical disorder

4 What, then, is PSYCHOSIS? Generally equated with positive symptoms and disorganized or bizarre speech/behavior Impaired “reality testing” A syndrome present in many illnesses –remove known cause or treat underlying illness –treat symptomatically with antipsychotic medications

5 Other Uses for Antipsychotics Schizoaffective disorder, bipolar disorder, delusional disorder Off-label use for Tourette’s, autism spectrum disorders, to augment treatment in depression and OCD, dementia, aggression in children Medical treatment of nausea, hiccups

6 A bit more terminology….. ….before we blast off. Many names…. Not all the same thing….. Antipsychotics - neuroleptic - typical and atypical - first gen, second gen, third gen - phenothiazine, thioxanthene, butyrophenone - low, med, and hi potency (1 st gens) - chemical and trade names - chlorpromazine/thorazine; olanzapine/zyprexa

7 An Historical Timeline The state of affairs prior to the 1950s - available treatments very ineffective Early 1950s experimental use of chlorpromazine (thorazine) Once broadly introduced, institutions emptied out (* but a couple of caveats) First generation (typical) antipsychotics developed. Second generation begins with clozapine (1989)

8 A “Typical” (1 st Gen) Timeline FDA approval Generic Name Brand Name 1953 chlorpromazine (Thorazine) 1958 trifluoperazine (Stelazine) 1958 perphenazine (Trilafon) 1959 fluphenazine (Prolixin) 1959 thioridazine (Mellaril) 1967 haloperidol (Haldol) 1967 thiothixene(Navane) 1970 mesoridazine (Serentil) 1975 loxapine (Loxitane) 1977 molidone(Moban) 1984 pimozide(Orap)

9 Efficacy of Typical Antipsychotics

10 Mechanism of Action: Dopamine D2 receptor antagonist

11 Regions affected by D2 blockade Mesolimbic (midbrain – limbic) and mesocortical (midbrain – forebrain) pathways – Emotional, cognitive regulation and integration Nigrostriatal Pathway – Basal ganglia – movement Hypothalamus-pituitary – Hormones, motivation, regulatory processes Brain stem – Chemoreceptor trigger zone (compazine) – Descending RAS (reticular activating system)

12

13 Dopamine related side effects profile Extrapyramidal side effects (EPS) – Extrapyramidal movement system/basal ganglia – Drug induced Parkinson’s (aka “Thorazine shuffle”) – Acute dystonias – Akathesia – Tardive dyskinesia (sensitization, upregulation?) – Hypothalamic pituitary – Neuroleptic malignant syndrome (high fever, sweating, unstable blood pressure, stupor, muscular rigidity, and autonomic dysfunction). Aggressive medical care needed. – Heat regulation and susceptibility to heat stroke – Increased prolactin – Sexual side effects

14 Other Mechanism of Action Table 4: Clinical Potency and Receptor Affinity for Typical Antipsychotic Agents Receptor type r with Potency Dopamine D1.41 Dopamine D2.94 Norephinephrine.24 (hypotension, sedation) Acetylcholine -.74 (anticholinergic effects) Serotonin.32 Histamine -.44 (sedation) From Baldesarrini, 1985

15 Anticholinergic effects Memory deficits, clouded cognition Urinary retention, constipation Dry mouth Blurred vision Tachycardia

16 Limitations of D2 Blockers “The Law of Thirds” Treatment resistant cases Lack of improvement of negative symptoms EPS side effects

17

18 Next Gen #1 - Clozapine Introduction and withdrawal in 1970s Europe – Agranulocytosis Reintroduction in US – Works in some (30-60%) of treatment resistant patients – Does not produce EPS – Improve affect, reduce suicidality – Agranulocyctosis reversible if detected and drug discontinued (testing protocol – weekly, monthly)

19 What’s Atypical about Clozapine? NOT a strong D2 blocker (relatively speaking) Antagonizes other dopamine receptors Antagonizes 5-HT receptors Antagonizes histimine, muscarinic Ach, adrenergic NE

20 The Atypical Boom FDA approval Generic Name Brand Name 1990clozapine (Clozaril) 1994risperidone (Risperdal) 1996olanzapine (Zyprexa) 1997quetiapine (Seroquel) 2001ziprasidone (Geodon) 2002aripiprazole (Abilify) 2009iloperidone (Fanapt) 2009asenapine (Saphris)

21 A small sample of Next Gens Search to produce clozapine-like drug without agranulocytosis Prototype: Risperidone (Risperdal) – Dual action – block D2 and 5-HT2 receptors – Other 5-HT/D2 combos Olanzapine (Zyprexa) Sertindole (Serlect) Quetiapine (Seroquel) Ziprasidone (Geodon)

22 Strengths and Weaknesses of 2 nd Gens Able to dissociate clinical effects from EPS side effects – But for some, this is dose dependent Able to dissociate clinical effects from agranylocytosis – No need for WBC monitoring Have become wildly popular. Off label use, especially in young and old, has expanded. – Raises serious concerns

23 Strengths and Weaknesses of 2 nd Gens Expansion to vulnerable populations REAL concern. Initial promise not entirely fulfilled – Note CATIE and Cutlass studies reported in text Claims for superior efficacy over 1 st gens (for increased tolerability, superior performance with negative symptoms and in treatment refractory) not entirely supported. Tolerability - similarly lousy compliance rates Trade-off in side effects profiles

24 2 nd Gen Side Effects Metabolic syndrome – Weight gain – Blood sugar dysregulation Increase risk of developing type 2 diabetes Rapid and independent of weight gain Increased risk of cardiac problems – Stroke risk in dementia patients – Electrical activity of the heart (sudden cardiac death)

25 3 rd Gens Aripiprazole (Abilify) – 5-HT2 antagonist – Partial agonist at D2 and 5-HT1a D2 effects at low and high intrinsic dopamine levels Antidepressant effects, especially when combined with true antidepressants Amisulpride (Solian) – D2 and D3 blocker, but selectively in limbic regions (not basal ganglia) – Blocks dopamine autoreceptors (increase DA release)

26 Next: Theories of Schizophrenia Neurochemical Models – Dopamine Hypothesis – Glutamate Hypothesis Etiology – Structural anomalies – Heredity – Development Experimental Research Models


Download ppt "PSYC 342: Psychopharmacology ANTIPSYCHOTIC MEDICATIONS."

Similar presentations


Ads by Google